Correction of neutrophil chemotaxis defect in patients with Gaucher disease by low-dose enzyme replacement therapy

Am J Hematol. 1993 May;43(1):69-71. doi: 10.1002/ajh.2830430118.

Abstract

We have recently described a chemotactic defect in severely afflicted Gaucher disease patients. Two of the patients were treated with low-dose intravenous enzyme replacement (Ceredase). Marked improvement in their hematological status, organomegaly, and growth was observed. In addition, their chemotactic defect and their tendency towards infections were corrected within 1 year of treatment.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chemotaxis, Leukocyte / drug effects*
  • Child, Preschool
  • Gaucher Disease / blood*
  • Gaucher Disease / drug therapy*
  • Glucosylceramidase / therapeutic use*
  • Humans
  • Male
  • Neutrophils / drug effects
  • Neutrophils / physiology*
  • Time Factors

Substances

  • alglucerase
  • Glucosylceramidase